Subchronic toxicity testing is a core repeated-dose safety study that evaluates the adverse effects of a substance after daily exposure for 28 to 90 days, providing critical data on target organ toxicity, dose–response relationships, and the no observed adverse effect level (NOAEL). As a mandatory data requirement for chemical registration, pesticide approval, food safety evaluation, and medical device biocompatibility under frameworks such as OECD TG 408, EPA OCSPP 870.3100, and the GB 15193 series, these studies are typically performed in GLP-accredited third-party laboratories. This article explains the study design, tested parameters, internationally recognized methods, and typical applications of subchronic toxicity testing.
Technical Overview
Subchronic toxicity testing, also known as repeated-dose toxicity testing, is a pivotal in vivo safety assessment designed to characterize the adverse health effects of a substance following repeated daily exposure over an extended but non-lifetime period. In regulatory toxicology, the subchronic study conventionally refers to a 90-day (13-week) exposure regimen, which corresponds approximately to 10 percent of a laboratory rodent's lifespan. Shorter 28-day repeated-dose studies are generally described as subacute, while studies of six months or longer approach chronic duration.
The primary objectives of a subchronic toxicity study are to identify target organs and tissues, characterize dose–response relationships, determine the no observed adverse effect level (NOAEL) and the lowest observed adverse effect level (LOAEL), and reveal cumulative, delayed, or reversible toxicity that is not evident in single-dose acute tests. The resulting data also provide dose justification for longer-term chronic, carcinogenicity, and reproductive toxicity studies, and support the derivation of acceptable daily intakes (ADI), reference doses, and occupational exposure limits.
Subchronic studies are normally conducted in compliance with Good Laboratory Practice (GLP) principles in accredited third-party laboratories, using at least one rodent species (commonly the rat) and, for certain regulatory frameworks, a second non-rodent species such as the beagle dog. Exposure is administered via the oral route (gavage, diet, drinking water, or capsule), dermal route, or inhalation route, selected to reflect realistic human exposure scenarios.
Testing Samples
Industrial Chemicals and New Substances
Industrial chemicals, solvents, monomers, intermediates, surfactants, and nanomaterials intended for market placement frequently require subchronic data packages for inventory registrations and new chemical notifications under chemical control regulations modeled on REACH-type frameworks, including tiered notification schemes in China, Korea, and other jurisdictions.
Pesticides and Agrochemicals
Active substances, formulated products, significant metabolites, and relevant impurities are evaluated with 90-day oral, dermal, or inhalation studies as part of the core data requirements for pesticide registration submitted to national regulatory authorities.
Food-Related Substances
Food additives, novel foods, health and functional foods, natural extracts, food enzymes, processing aids, feed additives, and food contaminants are assessed under food safety toxicological evaluation programs, notably the GB 15193 national food safety standard series, which specifies a 90-day oral toxicity test as a central component of the testing hierarchy.
Cosmetics and Consumer Products
Ingredients with potential systemic exposure, household chemical products, biocidal active substances, and finished consumer goods may require repeated-dose systemic toxicity data or weight-of-evidence justification depending on the applicable regional regulatory framework.
Pharmaceuticals and Medical Devices
Active pharmaceutical ingredients, impurities, degradation products, and excipients are supported by repeated-dose studies consistent with ICH guidance on nonclinical safety studies, while medical device extracts and materials are evaluated for subacute and subchronic systemic toxicity under the ISO 10993-11 biocompatibility standard within the overall ISO 10993-1 risk management framework.
Testing Items
In-Life Observations
- Mortality and morbidity checks performed at least twice daily
- Detailed clinical observations and cage-side assessments of skin, fur, mucous membranes, posture, and behavior
- Functional observational battery or modified Irwin screen, including grip strength and locomotor activity
- Body weight measurement and food and water consumption recording at regular intervals
- Ophthalmoscopic examinations performed before dosing and at terminal sacrifice
Clinical Pathology
- Hematology: erythrocyte count, hemoglobin, hematocrit, MCV, MCH, MCHC, reticulocytes, total and differential leukocyte counts, platelet count, prothrombin time, and activated partial thromboplastin time
- Clinical chemistry: ALT, AST, ALP, GGT, total bilirubin, urea, creatinine, glucose, total protein, albumin, globulin, albumin/globulin ratio, cholesterol, triglycerides, and key electrolytes including sodium, potassium, chloride, calcium, and phosphorus
- Urinalysis: volume, color, specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, occult blood, and urinary sediment microscopy
Necropsy, Organ Weights, and Histopathology
- Full gross necropsy examination of all animals, including those found dead or sacrificed in extremis
- Absolute and relative organ weights for brain, heart, liver, kidneys, adrenals, spleen, thymus, thyroid with parathyroids, and reproductive organs, with paired organs weighed separately
- Histopathological examination of a comprehensive tissue list covering more than 40 organs and tissues, initially on control and high-dose animals and extended to lower dose groups when treatment-related findings are detected
- Optional satellite or recovery groups to assess the reversibility of observed effects after a treatment-free period
Supplementary Endpoints
Depending on regulatory needs, studies may incorporate toxicokinetic blood sampling, sperm motility and morphology assessments, vaginal cytology and estrous cyclicity evaluation as screening for reproductive toxicity, thyroid hormone measurements, and additional mechanistic biomarkers.
Testing Methods
Internationally Recognized Guidelines
- OECD TG 407: Repeated Dose 28-Day Oral Toxicity Study in Rodents
- OECD TG 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents
- OECD TG 409: Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents
- OECD TG 411: Subchronic Dermal Toxicity Study (90-Day)
- OECD TG 413: Subchronic Inhalation Toxicity Study (90-Day)
- EPA OCSPP 870.3100, 870.3250, and 870.3465 covering 90-day oral, dermal, and inhalation toxicity, respectively
- GB/T 21763 for subchronic oral toxicity testing of chemicals and GB 15193.26 within the GB 15193 series for food safety evaluation
- ISO 10993-11 for subacute and subchronic systemic toxicity testing of medical devices
Study Design Elements
A dose-range finding study, often a 14-day probe, is usually conducted first to support dose selection. The definitive study includes a minimum of three dose levels plus a concurrent vehicle control group, with the high dose selected to induce evident toxicity without excessive mortality or severe suffering, and a limit dose conventionally set at 1000 mg/kg body weight per day when no toxicity is expected. Rodent studies typically use at least 10 animals per sex per group, increasing to 20 per sex when recovery animals are included, while canine studies commonly use 4 animals per sex per group. Animals are randomized to groups, housed under controlled environmental conditions, and fed certified diets, and all data are evaluated with appropriate statistical methods including analysis of variance and dose–response trend testing. Full compliance with OECD GLP principles or equivalent national GLP regulations is mandatory for studies intended for regulatory submission.
Applications
Subchronic toxicity data serve as foundational evidence across virtually all product safety regulatory programs:
- Chemical inventory registration and new chemical notification, where tonnage- or volume-based tiers trigger 28-day and 90-day study requirements
- Pesticide and biocide registration dossiers submitted to national regulatory authorities
- Food safety evaluation and approval of food additives, novel foods, and health foods
- Medical device biocompatibility assessment and risk management documentation
- Pharmaceutical development, supporting the permitted duration of clinical dosing
- Derivation of acceptable daily intake values, reference doses, and occupational exposure limits from the NOAEL using appropriate uncertainty factors
- GHS classification for specific target organ toxicity following repeated exposure (STOT RE)
- Weight-of-evidence assessments, read-across justifications, and category approaches in integrated testing strategies
FAQ
What is the difference between subacute and subchronic toxicity studies?
Subacute studies involve repeated dosing for approximately 28 days, while subchronic studies extend exposure to 90 days. The longer subchronic design provides greater sensitivity for detecting cumulative effects, allows more reliable characterization of dose–response relationships, and is the standard duration required for most registration purposes, whereas subacute studies often serve as range-finding or screening tools.
How is the NOAEL determined?
The NOAEL is the highest tested dose at which no statistically or biologically significant treatment-related adverse effects are observed. It is established by integrating all in-life observations, clinical pathology results, organ weight changes, and histopathological findings, and it forms the anchor point for calculating safe exposure levels in human health risk assessment.
Which species are used, and how many animals are required?
Most programs require a rodent species, typically the rat, and many additionally require a non-rodent species such as the dog. Rodent groups generally include at least 10 animals per sex per dose level, while canine groups typically include 4 animals per sex per dose level.
How long does a subchronic study take?
The in-life dosing phase lasts 90 days, but the complete study, including acclimation, dose formulation, necropsy, histopathology processing and evaluation, and report finalization, typically requires six to nine months from study initiation under a well-managed GLP quality system.
Can alternatives replace animal subchronic studies?
Adverse outcome pathway frameworks, in vitro defined approaches, and computational models continue to advance, and certain specific endpoints now have accepted alternatives. However, for comprehensive systemic repeated-dose toxicity required in most chemical, pesticide, and food registration frameworks, subchronic in vivo studies remain the internationally accepted standard, although waivers based on robust read-across or exposure-based arguments may be justified in defined circumstances.